Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC) Meeting Abstract

International Collaboration

cited authors

  • Grivas, Petros; Daneshmand, Siamak; Makarov, Vladimir; Bellmunt, Joaquim; Sridhar, Srikala S.; Sonpavde, Guru P.; Cole, Suzanne; Tripathi, Abhishek; Faltas, Bishoy Morris; Lerner, Seth P.; Fleming, Mark T.; Loriot, Yohann; Meeks, Joshua J.; Master, Viraj A.; Davis, Kimberlee; Van Veenhuyzen, David Friedrich; Afifi, Shugufa; Pal, Sumanta Kumar; Gupta, Shilpa

Publication Date

  • June 1, 2023

webpage

published in

category

volume

  • 41

issue

  • 16